Pancreatic Cancer Research

ResearcherUniversité de BordeauxActive in the last 2 years

Simon Pernot

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4580-585X; OpenAlex author ID A5070237613. Sources: ClinicalTrials.gov.

Their work

Papers
13 (first author 3, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers, 1 trial

Papers 13

  1. Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic… First author DOI 10.1016/j.eclinm.2026.103998↗
  2. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Co-author DOI 10.1038/s41591-026-04327-4↗
  3. Extensive molecular profiling of KRAS wild-type as compared to KRAS mutated pancreatic ductal adenocarcinoma on 318 patients. Co-author DOI 10.1016/j.ejca.2024.115197↗
  4. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  5. Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should KRAS mutation research be recommended in everyday practice? Co-author DOI 10.1177/17562848231224943↗
  6. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Last author DOI 10.1038/s41416-022-01713-w↗
  7. Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world A… Last author DOI 10.1038/s41416-022-01734-5↗
  8. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter … Co-author DOI 10.1016/j.clinre.2019.08.009↗
  9. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/j.ejca.2020.05.018↗
  10. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Co-author DOI 10.1177/1756284819878660↗
  11. Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre coh… Co-author DOI 10.1038/bjc.2016.70↗
  12. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. First author DOI 10.1038/bjc.2015.328↗
  13. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. First author DOI 10.1016/j.clinre.2014.01.005↗

Trials 1

  1. Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma Principal investigator NCT06705335↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julien Taı̈eb · 9 shared papers, 2014–2026 · strength 0.98
  2. David Tougeron · 7 shared papers, 2015–2026 · strength 0.85
  3. Dominique Béchade · 6 shared papers, 2019–2025 · strength 0.80
  4. Jean‐Baptiste Bachet · 4 shared papers, 2015–2026 · strength 0.51
  5. Jeanne Léna · 2 shared papers, 2024–2025 · strength 0.46
  6. Antoîne Italiano · 2 shared papers, 2024–2025 · strength 0.46
  7. Lola‐Jade Palmieri · 2 shared papers, 2024–2025 · strength 0.46
  8. Anne‐Laure Pointet · 3 shared papers, 2019–2025 · strength 0.33
  9. Isabelle Trouilloud · 3 shared papers, 2019–2025 · strength 0.33
  10. Nicolas Williet · 3 shared papers, 2019–2025 · strength 0.33
  11. Alix Portal · 4 shared papers, 2014–2025 · strength 0.33
  12. Sonia Zaibet · 2 shared papers, 2022 · strength 0.26
  13. Édouard Auclin · 2 shared papers, 2022 · strength 0.26
  14. Astrid Lièvre · 2 shared papers, 2022 · strength 0.26
  15. Matthieu Sarabi · 2 shared papers, 2022 · strength 0.26
  16. Julien Edeline · 2 shared papers, 2022 · strength 0.26
  17. Marine Gilabert · 2 shared papers, 2022 · strength 0.26
  18. Émilie Soularue · 2 shared papers, 2020–2025 · strength 0.26
  19. Jean–Marc Phelip · 2 shared papers, 2019–2025 · strength 0.24
  20. Carole Vitellius · 1 shared paper, 2026 · strength 0.22
  21. Yves Rinaldi · 1 shared paper, 2026 · strength 0.22
  22. Frédéric Di Fiore · 1 shared paper, 2026 · strength 0.22
  23. Anna Pellat · 1 shared paper, 2026 · strength 0.22
  24. Côme Lepage · 1 shared paper, 2026 · strength 0.22
  25. Rachna T. Shroff · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.